JNJ241213P175000
- 0.00
- 0.000.00%
Johnson & Johnson Newsroom
Weekly Buzz: Tech stocks hit high scores on ominous day
J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds -- WSJ
Express News | Johnson & Johnson Shares up 0.4%
Express News | Cigna Shares Pare Gains, Last up 0.2%; Wall Street Journal Reports Johnson & Johnson Has Sued Divisions of Cigna
"J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds; Pharmaceutical Company Claims Cigna Units Worked With SaveOn and Caused It to Pay More Than $100 Million in Copay Assistance Than It Would Have Otherwise" - WSJ
Johnson & Johnson Options Trading: A Deep Dive Into Market Sentiment
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ACTION Centers Collaborate With Johnson & Johnson MedTech to Secure FDA Labeling for Impella Support System in Pediatric Patients
Market Mixed on Friday the 13th | Livestock
Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181
Insider Purchase: Director at $JNJ (JNJ) Buys 1,000 Shares
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Thursday Ends in Index Declines | Wall Street Today
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix
U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients
Today's Analyst Rating | Citi Cuts Its Price Target Cut on Johnson & Johnson to $175, Deutsche Bank Upgrades Coca-Cola to Buy
Jim Cramer Bullish On Netflix Nearing $1,000 And AMD's 'Cheap' Valuation Despite Nvidia Dominance
The latest research results of Johnson & Johnson (JNJ.US) CAR-T Therapy have been announced.
Johnson & Johnson (JNJ.US) recently announced the latest research results of the phase 3 clinical trial CARTITUDE-4.